SightfileU.S. market data from official filings

Companies › BGLC

BIONEXUS GENE LAB CORP (BGLC)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001737523 · EDGAR filings · Updated 2026-07-28

BIONEXUS GENE LAB CORP (BGLC) has 2 institutional managers reporting positions valued at $497 per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Institutional managers
2
Reported 13F value
$497
Data flags
2 active
from SEC filings

Filings this week (1)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, BIONEXUS GENE LAB CORP has 2 institutional holders.

Data flags from SEC filings

Active substantial-doubt (going concern) disclosure per the filings, most recently filed 2026-05-15 (recurring since 2025-04-15) — source filing. The authoritative details are those stated in the filing itself.
Active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), most recently filed 2025-04-30 (recurring since 2023-11-13) — source filing. The authoritative details are those stated in the filing itself.

Related companies

NEWCELX LTD (NCEL) · ABPRO HLDGS INC (ABPO) · VASO CORPORATION (VASO) · CHARLIES HLDGS INC COM NEW (CHUC) · Edgemode Inc (EDGM) · HEALTHLYNKED CORP COM (HLYK)

See full history, cross-references and alerts on Sightfile
Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-28.